Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 1;31(3):374-383.
doi: 10.53854/liim-3103-11. eCollection 2023.

Comparative outcomes of direct-acting antiviral treatment in patients with HIV-Hepatitis C co-infection: insights from a single center experience in Colombia

Hernán Vergara-Samur  1 , Samuel Martínez-Vernaza  1   2 , Alejandro De la Hoz  1   2   3 , Julián Barahona-Correa  4 , Juan Pablo Ortiz  1 , Sandra Gualtero-Trujillo  1   2 , José Rumbo-Romero  4 , Luis Miguel Salazar  1 , Yanette Suárez Quintero  5 , Sandra Valderrama-Beltrán  1   2
Affiliations

Comparative outcomes of direct-acting antiviral treatment in patients with HIV-Hepatitis C co-infection: insights from a single center experience in Colombia

Hernán Vergara-Samur et al. Infez Med. .

Abstract

Background: Direct-acting antivirals (DAA) were introduced to Latin America with the aim of eliminating hepatitis C (HCV) in the region. There are scarce data on the outcomes of people living with HIV and HCV treated with these medications in Colombia. This study compares the outcomes of patients with HIV-HCV co-infection and HCV mono-infection treated with DAAs.

Methods: Retrospective observational study including patients ≥18 years old with HCV infection treated with DAAs from August 2017 to December 2019 in a comprehensive center in Colombia. The main outcome was sustained virologic response (SVR). Secondary outcomes included reinfection, relapse and adverse events.

Results: We included 223 individuals with HCV treated with DAAs; 142 (63.6%) individuals were mono-infected and 81 (36.3%) co-infected. Genotypes 1b (49.7%) and 4 (33.9%) were the most common. Overall SVR after DAA treatment was 96.8%. Relapse rate was 2.24%, reinfection rate was 6.28% and adverse events occurred in 27.8% of cases. SVR was comparable in patients with co- and mono-infection (95% vs 97.8%, p=0.245).

Conclusion: DAA were effective in mono-infected (HCV) and co-infected (HCV/HIV) patients and reinfection was high in this last group.

Keywords: Colombia; Direct-Acting Antivirals; Hepatitis C; Human Immunodeficiency virus.

PubMed Disclaimer

Conflict of interest statement

Conflict of interests The authors have no conflict of interests to declare.

Similar articles

See all similar articles

Cited by

References

    1. Alvarado-Mora MV, Rebello Pinho JR. Epidemiological update of hepatitis B, C and delta in Latin America. Antivir Ther. 2013;18:429–433. - PubMed
    1. Ministerio de Salud y Protección Social. Guía de Práctica Clínica Para la tamización, diagnóstico y tratamiento de personas con infección por el virus de la hepatitis C. Bogotá: 2018. http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Otros_conv/GPC_hepatiti... .
    1. Alvis-Guzman N, Romero M, De la Hoz-Restrepo F. Burden of disease of Hepatitis C in Colombia. Value Heal. 2015;18:A250–A251.
    1. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16:797–808. - PubMed
    1. Martin NK, Boerekamps A, Hill AM, et al. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it? J Int AIDS Soc. 2018;21:e25062. - PMC - PubMed

LinkOut - more resources